Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Newly Approved Drug for Metastatic Melanoma Nearly Doubles Median Survival

24.02.2012
Researchers from UCLA’s Jonsson Comprehensive Cancer Center, together with scientists from 12 other sites in the United States and Australia, report for the first time that a newly approved drug for patients with metastatic melanoma nearly doubles median survival times, a finding that will change the way this deadly form of skin cancer is treated.

The data comes from an international Phase II study of Zelboraf that included 132 patients followed for at least one year.

Patients with this advanced form of melanoma that has spread to other organs typically survive about nine months. Patients taking Zelboraf, which blocks a mutated BRAF protein, survived an average of 15.9 months, said study senior author Dr. Antoni Ribas, a professor of hematology/oncology and a researcher at UCLA’s Jonsson Cancer Center.

“This study shows that Zelboraf changes the natural history of this disease,” Ribas said. “This data is beyond what I would have expected. We’re seeing a significant number of patients with durable responses to the drug, and that the whole group of treated patients is living longer. These results tell us that this drug is having a very big impact, and this changes the way we treat metastatic melanoma.”

The study appears Feb. 23, 2012 in the peer-reviewed New England Journal of Medicine.

About 50 percent of patients with metastatic melanoma, or 4,000 people a year, have the BRAF mutation and can be treated with Zelboraf, a pill taken twice a day, Ribas said. Of those, 53 percent have an objective response to the drug, meaning their tumors shrink by more than 30 percent. An additional 30 percent of patients have tumor responses of lesser magnitude. Only 14 percent of patients with the BRAF mutation failed to respond to Zelboraf.

The drug represents a breakthrough in treating metastatic melanoma. Prior to this, 10 percent or less of patients with this advanced form of the disease responded to any of the available conventional treatments, Ribas said.

“We knew this drug would make the melanomas shrink in a large proportion of patients and that it worked better than chemotherapy,” Ribas said. “We did not know that patients taking Zelboraf were living longer until now.”

The main limitation with Zelboraf is that tumors eventually become resistant. But Jonsson Cancer Center researchers are studying this resistance and have uncovered several mechanisms by which the cancer gets around Zelboraf. Cancer center scientists currently are seeking agents to target those mechanisms, Ribas said.

For Louise Belley, 60, of Santa Ana, Zelboraf has allowed her to live much longer than her doctors initially predicted, and last June she was able to see her daughter graduate from college. Belley was diagnosed with metastatic melanoma in November of 2007. In June 2009, she was among the first people to get the drug when it was in Phase I studies at the Jonsson Cancer Center.

Her first CT scan in September 2009 after joining the trial - nearly two and a half years ago - was clear of any cancer, she said. Her scans remain clean today.

“At first I was devastated by my diagnosis, because I realized I was in a really bad place,” Belley said. “But now I feel strongly that the chances are good that I will continue to be cancer free, and I plan to live every day to the fullest.”

Zelboraf was approved by the U.S. Food and Drug Administration for use in metastatic melanoma in August of 2011. About 70,000 new cases of melanoma are diagnosed each year in the United States. Of those, 8,000 people will die of the disease.

“This trial shows a high rate of response to (Zelboraf) in patients with metastatic melanoma and activating BRAF mutations,” the study states. “These results independently confirm the high response rate and response duration shown in a Phase I trial.”

UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2011, the Jonsson Cancer Center was named among the top 10 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 11 of the last 12 years. For more information on the Jonsson Cancer Center, visit our website at http://www.cancer.ucla.edu.

Kim Irwin | Newswise Science News
Further information:
http://www.mednet.ucla.edu

Further reports about: BRAF Cancer Drug Delivery Ribas melanoma metastatic metastatic melanoma

More articles from Life Sciences:

nachricht First use of vasoprotective antibody in cardiogenic shock
17.05.2019 | Deutsches Zentrum für Herz-Kreislauf-Forschung e.V.

nachricht A nerve cell serves as a “single” for studies
15.05.2019 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Self-repairing batteries

UTokyo engineers develop a way to create high-capacity long-life batteries

Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a...

Im Focus: Quantum Cloud Computing with Self-Check

With a quantum coprocessor in the cloud, physicists from Innsbruck, Austria, open the door to the simulation of previously unsolvable problems in chemistry, materials research or high-energy physics. The research groups led by Rainer Blatt and Peter Zoller report in the journal Nature how they simulated particle physics phenomena on 20 quantum bits and how the quantum simulator self-verified the result for the first time.

Many scientists are currently working on investigating how quantum advantage can be exploited on hardware already available today. Three years ago, physicists...

Im Focus: Accelerating quantum technologies with materials processing at the atomic scale

'Quantum technologies' utilise the unique phenomena of quantum superposition and entanglement to encode and process information, with potentially profound benefits to a wide range of information technologies from communications to sensing and computing.

However a major challenge in developing these technologies is that the quantum phenomena are very fragile, and only a handful of physical systems have been...

Im Focus: A step towards probabilistic computing

Working group led by physicist Professor Ulrich Nowak at the University of Konstanz, in collaboration with a team of physicists from Johannes Gutenberg University Mainz, demonstrates how skyrmions can be used for the computer concepts of the future

When it comes to performing a calculation destined to arrive at an exact result, humans are hopelessly inferior to the computer. In other areas, humans are...

Im Focus: Recording embryonic development

Scientists develop a molecular recording tool that enables in vivo lineage tracing of embryonic cells

The beginning of new life starts with a fascinating process: A single cell gives rise to progenitor cells that eventually differentiate into the three germ...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

 
Latest News

Discovering unusual structures from exception using big data and machine learning techniques

17.05.2019 | Materials Sciences

ALMA discovers aluminum around young star

17.05.2019 | Physics and Astronomy

A new iron-based superconductor stabilized by inter-block charger transfer

17.05.2019 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>